Pharmesis International Ltd.

BFK

SG1BH6000003

Pharmaceuticals

Market Closed - Singapore S.E. Other stock markets 12:44:16 25/06/2024 pm IST			5-day change	1st Jan Change
0.081 ^SGD	-23.58%		-23.58%	-17.35%

14/06	Singapore Shares Down Tracking Global Market Losses; Soilbuild Soars 147%	MT
14/06	Pharmesis International Completes Subscription Deal Following Share Issue; Shares Surge 32%	MT

Pharmesis International Ltd. Appoints Liang Chan Hoe as Financial Controller, Effective June 1, 2016

May 31, 2016 at 02:42 pm IST

Pharmesis International Ltd. announced appointment of Mr. Liang Chan Hoe as Financial Controller. He will be responsible for the Group's accounting and finance functions. Date of appointment is June 1, 2016.

Latest news about Pharmesis International Ltd.

Singapore Shares Down Tracking Global Market Losses; Soilbuild Soars 147%	14/06	MT
Pharmesis International Completes Subscription Deal Following Share Issue; Shares Surge 32%	14/06	MT
Pharmesis International Secures Approval for Listing of Over 4 Million Shares	05/06	MT
Pharmesis International Ltd. Announces Board Appointment and Changes to the Composition of the Board and Board Committees	31/05	CI
Pharmesis International Enters Subscription Agreement for 4.1 Million Additional Shares	29/05	MT
Pharmesis to Issue 4 Million New Shares Under Placement	28/05	MT
Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	30/04	CI
Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	30/04	CI
Pharmesis International Ltd. Announces Retirement of Lin Yimin as Member of Audit Committee	29/04	CI
Pharmesis’ Attributable Loss for 2023 Widens	15/04	MT
Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director	15/04	CI
Pharmesis Launches New Product Line	26/03	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months and Full Year Ended 31 December 2023	28/02	CI
Pharmesis International Ltd. Announces Changes to the Composition of the Board and Board Committees	29/23/29	CI
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI
Pharmesis International Flags Losses for H1	09/23/09	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	08/23/08	CI
Pharmesis International Ltd. Announces Management Resignations	31/23/31	CI
Pharmesis International Ltd. Appoints Lin Yimin as Non-Independent Non-Executive Director and A Member of Audit Committee	31/23/31	CI
Pharmesis International Ltd. Announces Temporary Work Stoppages at its Manufacturing Facilities Located in Gulin County, Luzhou City, Sichuan Province	27/23/27	CI
Pharmesis International Issues 4.6 Million Shares to Two Subscribers	06/23/06	MT
Pharmesis International Gets Regulatory Nod to List 4.6 Million Shares	29/23/29	MT
Pharmesis International to Issue 4.6 Million Shares to Two Subscribers	21/23/21	MT
Pharmesis International Expects Loss in H2, FY22	28/23/28	MT

Chart Pharmesis International Ltd.

Duration

Period

More charts

Company Profile

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMESIS INTERNATIONAL LTD.	-17.35%	18.94L
ELI LILLY AND COMPANY	+55.32%	82TCr
NOVO NORDISK A/S	+44.05%	64TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	22TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr